Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

Trial StartKIMMTRAKPositive

AI Analysis

Summary

Immunocore announced that its registrational TEBE-AM trial of KIMMTRAK (tebentafusp) in previously treated advanced melanoma has achieved target enrollment. This milestone represents progress toward potential regulatory submission for the immunotherapy candidate.

Clinical Trial Data

Outcome Details

Target enrollment achieved in registrational TEBE-AM trial

Importance:6/10

Sentiment:

0.60

melanomaoncologyclinical trialenrollmentimmunotherapy

Related Companies

$IMCR

Read the original article

Published by yahoo_finance on September 14, 2026 11:00 AM

Read Original